<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1509</article-id><article-id pub-id-type="doi">10.15789/2220-7619-PSD-1509</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Parthenolide: suggested drug for COVID-19</article-title><trans-title-group xml:lang="ru"><trans-title>Партенолид: возможное лекарство от COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4262-1636</contrib-id><name-alternatives><name xml:lang="en"><surname>Nemati</surname><given-names>M.</given-names></name><name xml:lang="ru"><surname>Немати</surname><given-names>М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Biochemistry, School of Medicine. Urmia</p></bio><bio xml:lang="ru"><p/><p>Кафедра биохимии медицинского факультета.</p>Урмия</bio><email>mohadese.nemati@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2636-9856</contrib-id><name-alternatives><name xml:lang="en"><surname>Danesh Pouya</surname><given-names>F.</given-names></name><name xml:lang="ru"><surname>Данеш Пойа</surname><given-names>Ф.</given-names></name></name-alternatives><address><country country="IR">Iran, Islamic Republic of</country></address><bio xml:lang="en"><p>Department of Biochemistry, School of Medicine.</p><p> </p>Urmia</bio><bio xml:lang="ru"><p/><p>Кафедра биохимии медицинского факультета.</p>Урмия</bio><email>f_daneshpouya@hotmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9783-5156</contrib-id><name-alternatives><name xml:lang="en"><surname>Roshani Asl</surname><given-names>E.</given-names></name><name xml:lang="ru"><surname>Рохни Асл</surname><given-names>Е.</given-names></name></name-alternatives><address><country country="IR">Iran, Islamic Republic of</country></address><bio xml:lang="en"><p>Department of Biochemistry, School of Medicine.</p><p> </p>Urmia</bio><bio xml:lang="ru"><p/><p>Кафедра биохимии медицинского факультета.</p>Урмия</bio><email>eli.roshani@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1506-1909</contrib-id><name-alternatives><name xml:lang="en"><surname>Rami</surname><given-names>Y.</given-names></name><name xml:lang="ru"><surname>Расми</surname><given-names>Й.</given-names></name></name-alternatives><address><country country="IR">Iran, Islamic Republic of</country></address><bio xml:lang="en"><p>Yousef Rasmi - Department of Biochemistry, School of Medicine, Urmia University MS; Cellular and Molecular Research Center, Urmia UMS.</p><p>Urmia, Phone: +989143174740, Fax: +984432780801</p></bio><bio xml:lang="ru"><p>Юсеф Расми - кафедра биохимии медицинского факультета Урмийского УМН; Центр клеточных и молекулярных исследований, УМН.</p><p>Иран, Урмия, Тел.: +989143174740, Факс: +984432780801</p></bio><email>rasmiy@umsu.ac.ir</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Urmia University of Medical Sciences</institution></aff><aff><institution xml:lang="ru">Кафедра биохимии медицинского факультета Урмийского университета медицинских наук, Урмия, Иран</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Urmia University of Medical Sciences</institution></aff><aff><institution xml:lang="ru">1 Кафедра биохимии медицинского факультета Урмийского университета медицинских наук, Урмия, Иран&#13;
2  Центр клеточных и молекулярных исследований, Университет медицинских наук Урмия, Урмия, Иран</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-11-27" publication-format="electronic"><day>27</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>789</fpage><lpage>791</lpage><history><date date-type="received" iso-8601-date="2020-06-15"><day>15</day><month>06</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-07-04"><day>04</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Nemati M., Danesh Pouya F., Roshani Asl E., Rami Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Немати М., Данеш Пойа Ф., Рохни Асл Е., Расми Й.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Nemati M., Danesh Pouya F., Roshani Asl E., Rami Y.</copyright-holder><copyright-holder xml:lang="ru">Немати М., Данеш Пойа Ф., Рохни Асл Е., Расми Й.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/1509">https://iimmun.ru/iimm/article/view/1509</self-uri><abstract xml:lang="en"><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Parthenolide is a sesquiterpene lactone found in medicinal plants. It can inhibit several pro-inflammatory signaling pathways, in particular the ATPase activity of NLRP3. Based on its ability to suppress inflammatory signal transduction and elevated level of serum IL-1β (a surrogate marker for NLRP3 activation) in COVID-19 patients, we suggest that PN could be potentiallyeffective for the treatment of COVID-19.</p></abstract><trans-abstract xml:lang="ru"><p>Новый коронавирус тяжелого острого респираторного синдрома (SARS-CoV-2) вызывает развитие респираторного дистресс-синдрома, являющегося основной причиной смерти пациентов. Одним из эффективных методов снижения воздействия этого вируса является партенолид (PN). Партенолид — сесквитерпе-новый лактон, содержащийся в лекарственных растениях, способный подавлять ряд провоспалительных сигнальных каскадов, в частности АТФ-азную активность инфламмасомы NLRP3. Учитывая его способность блокировать проведение воспалительных сигналов и повышенный уровень сывороточного цитокина IL-1β (как суррогатного маркера активации NLRP3) у пациентов с COVID-19, мы полагаем, что Партенолид мог бы быть эффективен при лечении COVID-19.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Parthenolide</kwd><kwd>COVID-19</kwd><kwd>NF-kB</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>партенолид</kwd><kwd>COVID-19</kwd><kwd>NF-kB</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Abad M.J., Guerra J.A., Bermejo P., Govil J., Singh V.K., Mishra S.K. Phytochemistry and pharmacology of Tanacetum: recent developments (2008).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B.G., Fitzgerald K.A., Hornung V., Latz E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol., 2009, vol. 183, no. 2, pp. 787—791. doi: 10.4049/jimmunol.0901363</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Dai Y., Guzman M.L., Chen S., Wang L., Yeung S.K., Pei X.Y., Dent P., Jordan C.T., Grant S. The NF (Nuclear factor)-KB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br. J. Haematol., 2010, vol. 151, no. 1, pp. 70—83. doi: 10.1111/j.1365-2141.2010.08319.x</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Dammann K., Khare V., Gasche C. Tracing PAKs from GI inflammation to cancer. Gut, 2014, vol. 63, no. 7, pp. 1173—1184. doi: 10.1136/gutjnl-2014-306768</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Fitzgerald K.N. A few additional treatment possibilities for COVID19 (SARS Cov-2) addressing furin-like cleavage and pyropto-sis (caspase-1 activation of inflammasome NLRP3). URL: https://www.drkarafitzgerald.com/2020/03/25/a-few-additional-treat-ment-possibilities-in-covid19-sars-cov-2-addressing-furin-like-cleavage-and-pyroptosis-caspacin-1-activation-of-inflammasome-nlrp3 (10.09.2020)</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Juliana C., Fernandes-Alnemri T., Wu J., Datta P., Solorzano L., Yu J.W., Meng R., Quong A.A., Latz E., Scott C.P., Alnemri E.S. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem., 2010, vol. 285, no. 13,pp. 9792-9802. doi: 10.1074/jbc.M109.082305</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol., 2009, vol. 27, pp. 229-265.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Maruta H., He H. A mini-review for COVID-19 issue (2020). URL: http://apitherapy.com/wp-content/uploads/2020/06/Propolis-melatonin-artemisinin-and-other-substances-as-PAK1-blocking-Therapy-of-Pandemic-Coronaviral-Infection-2020-Australia.pdf (20.08.2020)</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med., 2020, vol. 46, no. 5, pp. 846-848. doi: 10.1007/s00134-020-05991-x</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Smolinski A.T., Pestka J.J. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. J. Inflamm., 2005, no. 2: 6. doi: 10.1186/1476-9255-2-6</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet, 2020, vol. 395, no. 10223, pp. 470-473. doi: 10.1016/S0140-6736(20)30185-9</mixed-citation></ref></ref-list></back></article>
